Type 1 diabetes

Socioeconomic and Linguistic Factors in Paediatric Type 1 Diabetes: Exploring Glycemic Outcomes, Technology Use, and Residual Beta‐Cell Function in Migrant‐Background Populations

Diabetes Obes MetabPublished Retrospective cohort study

Authors' conclusion

In this retrospective cohort, children and adolescents from migrant-background families had poorer glycemic outcomes despite high AID uptake and comparable C-peptide levels at follow-up.

Study context

Population
Children with paediatric T1D; median (IQR) age 11 (8–14) years
Participants
208 children
Exposure
Migrant-background vs Italian children with T1D
  • Migrant-backgroundn = 89
  • Italiann = 119reference
Outcome
Glycemic control (HbA1c, TIR, TITR, TAR, CV) and residual beta-cell function
Methodological detailsunivariable and exploratory multivariable regression
  • Univariable and exploratory multivariable regression

Main finding

As reported in the abstract

Glycemic control

Glycemic control

TIR

CV

  • Migrant-background vs Italian: P < 0.001 — value = HbA1c
  • Migrant-background vs Italian: P = 0.004
  • Migrant-background vs Italian: P < 0.001

Observational data: associations, not effects.

Further findings

C-peptide at onset

P = 0.010

AID usage

OutcomeMigrant-backgroundItalianP value
pH at onset7.287.35P = 0.047

Maternal unemployment

Migrant mothers unemployed vs comparison mothers
63.4% vs 16.6%, p < 0.001

Multivariable analysis

Migrant status associated with higher HbA1c
β +0.70, p < 0.001
AID use associated with higher TIR
β +10, p < 0.001
High maternal education associated with higher TIR
β +7.86, p = 0.004
  • Exploratory

Original publication

Socioeconomic and Linguistic Factors in Paediatric Type 1 Diabetes: Exploring Glycemic Outcomes, Technology Use, and Residual Beta‐Cell Function in Migrant‐Background Populations. Diabetes Obes Metab. Published 2 August 2026. doi:10.1111/dom.71167

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.